J. Goldman & Co’s Ocular Therapeutix OCUL Stock Holding History

J. Goldman & Co’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$999K	Buy	+101,760	New	+$922K	0.03%	464

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

J. Goldman & Co's OCUL Position: Q2 2026 in Review

J. Goldman & Co opened a new position in Ocular Therapeutix (OCUL) in Q2 2026: 101,760 shares worth $999K. The stake represents 0.03% of the portfolio and ranks #464 among its holdings.

261 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

J. Goldman & Co held 101,760 shares of Ocular Therapeutix worth $999K as of Q2 2026.
Ocular Therapeutix was a new J. Goldman & Co position in Q2 2026.
Ocular Therapeutix made up 0.03% of J. Goldman & Co's portfolio in Q2 2026, its #464 holding.
261 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.